Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 159-162

  Breccia, Massimo ^a   Federico, Vincenzo ^a   Latagliata, Roberto ^a   Mercanti, Caterina ^a   D'Elia, Gianna Maria ^a   Cannella, Laura ^a   Loglisci, Giuseppina ^a   Salaroli, Adriano ^a   Santopietro, Michelina ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Comorbidities; Myelodysplastic syndromes; Survival

Indexed keywords

ADULT; ADVERSE OUTCOME; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX; HUMAN; INTERMETHOD COMPARISON; KIDNEY DISEASE; LEUKOCYTE COUNT; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELODYSPLASTIC SYNDROME SPECIFIC COMORBIDITY INDEX; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK ASSESSMENT; SCORING SYSTEM; SOLID TUMOR; SYNDROME DELINEATION; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART DISEASES; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78751705026     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.005     Document Type: Article

References (14)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
2. Greenberg P., Cox C., Le Beau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Bennett J.M., Catowsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
4. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
5. Germing U., Gattermann N., Strupp C., Aivaado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
6. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
7. Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis 1970, 23:455-468.
8. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
9. Breccia M., Frustaci A.M., Cannella L., Stefanizzi C., Latagliata R., Cartoni C., et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol 2009, 27:148-153.
10. Zipperer E., Pelz D., Nachtkamp K., Kuendgen A., Strupp C., Gattermann N., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729-732.
11. Wang R., Gross C.P., Halene S., Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009, 33:1594-1598.
12. Sperr W.R., Wimazal F., Kundi M., Baumgartner C., Nösslinger T., Makrai A., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010, 21:114-119.
13. Birim O., Kappetein A.P., Bogers A.J.J.C. Charlson comorbidity index as a predictor of long-term outcome after surgery for non-small cell lung cancer. Eur J Cardiothorac Surg 2005, 28:759-762.
14. Della Porta M., Kuenggen A., Malcovati L., Zipperer E., Pascutto C., Travaglino E., et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood 2008, 112:2677.